In conclusion, based on this preclinical evidence, the RANK-RANKL-osteoprotegerin interactions and modulations may constitute an emerging therapeutic mediator for the treatment of periodontitis and alveolar bone loss, especially during the active phases of the disease. This evidence concerns the gene TNFRSF11B and periodontitis.